Trachoma Impact Survey Results from 31 Woredas in Tigray Region, Ethiopia

Baseline surveys were conducted in Tigray region, Ethiopia, in 2013. Since then, rounds of azithromycin mass drug administration (MDA) have been delivered in-line with international guidance. The purpose of these surveys was to assess trachomatous inflammation—follicular (TF) prevalence following those treatments to enable the region to plan the next steps towards elimination of trachoma.

All surveys followed WHO recommendations for community-based cross-sectional survey design. Thirty-one woredas in six zones of Tigray region were surveyed. There were two survey series: all 31 woredas were surveyed in the first series, and 11 woredas were resurveyed in the second, due to having a TF prevalence between 5% and 9.9% in the first series.

In the first series of 31 surveys, one woreda had an adjusted TF prevalence in 1−9-year-olds of <5.0%, 13 had a prevalence of 5.0−9.9% and 17 had a prevalence of 10.0−29.9%. In the second series of 11 surveys, the prevalence of TF was <5.0% in seven woredas and 5.0−9.9% in four woredas. The most recent adjusted prevalence of trachomatous trichiasis (TT) unknown to the health system in ≥15-year-olds was ≥.2% in 27 EUs. One-third of households visited had access to an improved drinking water source within a 30-minute return journey of their house, and 11% had an improved latrine.

Eight woredas met the criteria to stop MDA for 2 years before the re-survey. However, further rounds of MDA, additional efforts to improve water and sanitation access and ongoing strengthening of surgical services for TT are needed across Tigray.